Operating Income - Dizal Jiangsu Pharmaceutical Co Ltd (SSE:688192) - Alpha Spread
D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 33.4 CNY -7.2%
Market Cap: 13.6B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dizal Jiangsu Pharmaceutical Co Ltd
Operating Income Peer Comparison

Comparables:
6160
1801
9926
603392
300122

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Operating Income
-ÂĄ1.1B
CAGR 3-Years
-14%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
-ÂĄ1.5B
CAGR 3-Years
-51%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Operating Income
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ7B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
50%

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Operating Income?
Operating Income
-1.1B CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Operating Income amounts to -1.1B CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-43%

Over the last year, the Operating Income growth was -43%. The average annual Operating Income growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been -14% over the past three years , -43% over the past five years .

Back to Top